Oesophageal Disorders — Viva Defence

Opening statement (SASPOP, delivered aloud)

"Mr Atherton is a 70-year-old retired headmaster with long-segment Barrett's oesophagus that has progressed to confirmed low-grade dysplasia on surveillance, on a background of ischaemic cardiomyopathy, chronic kidney disease and anticoagulated atrial fibrillation. His main problems are: a premalignant oesophageal condition that has crossed the threshold where guidelines recommend endoscopic eradication rather than continued surveillance; procedural risk shaped by his cardiac function and anticoagulation; and the question of what he personally wants from treatment at this stage of his life. I would like to confirm the dysplasia, stage the segment properly, and then make an individualised decision with him about endoscopic eradication versus continued surveillance." [1]

Structured problem list

1. Confirmed low-grade dysplasia in a C2M5 Barrett's segment — two expert pathologists agree, so this is a treatment conversation, not a surveillance-intensification conversation [1].
2. Cardiac comorbidity — EF 40 per cent after anterior MI: sedation and procedural risk need anaesthetic assessment, and any intervention must be worth that risk.
3. Anticoagulation with apixaban for AF — endoscopic resection and ablation are higher-bleeding-risk procedures; periprocedural interruption and resumption timing must be planned, not improvised.
4. Stage 3 CKD — influences anaesthetic and medication choices and adds to his competing mortality risk.
5. The patient's frame — six years of surveillance means he may see himself as "watched and safe"; the shift to active treatment needs explanation, not assumption.

Integrated management plan

• Verify before acting: confirm both pathology reviews, and repeat high-definition endoscopy with narrow-band imaging to ensure no visible lesion has been missed — a visible nodule would change the sequence to endoscopic mucosal resection first, because EMR is both treatment and T-staging [1].
• Assess procedural risk honestly: anaesthetic review for sedation against an EF of 40 per cent; plan apixaban interruption and resumption with his cardiologist; document bleeding and perforation risk against his comorbidity.
• The default position — offer eradication: for confirmed low-grade dysplasia, the SURF trial showed radiofrequency ablation reduced progression to high-grade dysplasia or cancer from 26.5 per cent under surveillance to 1.5 per cent at three years; AIM Dysplasia established RFA's efficacy across dysplasia grades. So my starting position is EMR of any visible lesion followed by RFA of the flat segment [2] [3].
• The individualisation: in a man whose cardiac and renal disease may claim his life expectancy before his Barrett's does, continued 6–12 monthly surveillance remains a defensible alternative — and I would say so explicitly, because guideline defaults do not cancel competing-risk reasoning [1] [4].
• Whichever path: optimised twice-daily PPI, protocol biopsies per the Prague-mapped segment, and a shared, documented decision [5].

Probing questions with model answers

"Why not just keep surveying him every six months?" — "Because confirmed dysplasia is exactly the event surveillance exists to detect; once it is confirmed by two expert pathologists, the evidence says treat. SURF randomised this exact patient group and showed ablation cut progression to high-grade dysplasia or cancer from about one in four to about one in sixty-seven over three years. Surveillance at closer intervals watches a premalignant process we can eradicate — but I hold this against his cardiac risk, which is why the decision is individualised rather than automatic" [1] [2].

"What is the actual cancer risk if you do nothing?" — "In non-dysplastic Barrett's, population data put the annual risk around 0.1 to 0.3 per cent. Confirmed low-grade dysplasia raises that substantially — the SURF surveillance arm progressed at roughly 9 per cent per year — though that trial selected confirmed cases and real-world rates vary. I would give him both numbers honestly rather than a single frightening figure" [2] [4].

"Walk me through the treatment itself." — "First a meticulous re-endoscopy: any visible nodule is removed by EMR, which treats it and gives T-staging — submucosal invasion would take us out of the endoscopic paradigm entirely. The remaining flat dysplastic segment is then ablated with radiofrequency energy, typically over one to three sessions. Afterwards he needs intensive PPI therapy and surveillance for recurrent intestinal metaplasia, because eradication is a program, not an event" [1] [3].

"How do his anticoagulation and cardiomyopathy change your plan?" — "In three ways. Apixaban is interrupted around the procedure with a defined resumption plan agreed with cardiology, balancing his AF stroke risk against post-resection bleeding. Sedation is anaesthetist-led given an EF of 40 per cent. And his competing risks sharpen the consent conversation — the benefit of ablation accrues over years, and I need his life expectancy and his priorities in the same room as the trial data" [1].

"If the segment had shown no dysplasia, what would you have done?" — "Continued surveillance at a three-to-five-year interval on standard-dose PPI — non-dysplastic Barrett's does not justify ablation, because the annual cancer risk is too small to outweigh procedural risk for most patients. That contrast is the point of the dysplasia threshold" [1] [4].

Communication points

• Explain the diagnosis without alarm: dysplasia is a warning sign on a surveillance program that has done its job, and the treatment is endoscopic, not an oesophagectomy [1].
• Present both paths with numbers — progression risk treated and untreated, procedural bleeding and perforation risk, and what surveillance after eradication looks like [2].
• Document the shared decision and the anticoagulation plan explicitly; in a multimorbid patient, the quality of the reasoning is the management [1].